关键词:

肝硬化, 络病理论, 温肝通络法, 肝功能, 肝硬度, 肝纤维化

Abstract:

Objective　To explore the clinical effect of Wengan Tongluo method for patients with compensated hepatitis B cirrhosis. Methods　Seventy-six patients with compensated hepatitis B cirrhosis treated at Tai'an Traditional Chinese Medicine Hospital from August 2022 to July 2024 were selected for the randomized controlled trial, and were divided into a control group and an observation group by the random number table method, with 38 cases in each group. The control group was (40.61±4.98) years old; the disease course was (5.61±1.46) years. The observation group was (41.30±5.11) years old; the disease course was (5.85±1.63) years. Both groups were treated with routine liver protection and antiviral therapy; the control group were treated with Wuzhuyu Wengan Decoction, and the observation group with Wuzhuyu Wengan Decoction and umbilical moxibustion. The scores of traditional Chinese medicine syndromes, liver function [aspartate transaminase (AST), alaninetransaminase (ALT), albumin (ALB), and total bilirubin (TBil)], cirrhosis [liver stiffness measurement (LSM)], and hepatic fibrosis indicators [serum laminin (LN), hyaluronicacid (HA), type Ⅳ collagen (Ⅳ-C), and type III precollagen (PCⅢ)] were compared between the two groups. t and χ² tests were used for the statistical analysis. Results　After the treatment, the scores of abdominal distension, fatigue, poor appetite, and pale complexion were lower than those before the treatment in both groups, and the scores in the observation group were lower than those in the control group (all P<0.05); the levels of AST, ALT, ALB, and TBil were better those those before the treatment, and the levels in the observation group were better than those in the control group (all P<0.05); the LSM was lower than that before the treatment in both groups, and the LSM in the observation group was lower than that in the control group (P<0.05); the levels of LN, HA, Ⅳ-C, and PCⅢ were lower than those before the treatment, and the levels in the observation group were lower than those in the control group (all P<0.05). There was no statistical difference in the incidence rate between the control group and the observation group [7.89% (3/38) vs. 2.63% (1/38); correction χ²=0.264; P=0.607]. Conclusion　Wengan Tongluo method for patients with compensated hepatitis B cirrhosis can improve their traditional Chinese symptoms and liver function and reduce their liver stiffness and degree of liver fibrosis, and is safe.

Key words:

Cirrhosis, Luobing theory, Wengan Tongluo method, Liver Function, Liver stiffness, Liver fibrosis